TreatSMA

TreatSMA’s Short Film Competition

TreatSMA’s short film competition launches today, get your entries in by the 14th April to be in with a chance of winning a £50 Amazon voucher!

Judged by the amazing Winston George Ellis who is an actor, producer and martial artist. Born to Jamaican parents in Reading Berkshire, Winston is an accomplished British Actor.
He is known most for his work on The Dark Knight (2008), Pirates of the Caribbean: Dead Man’s Chest (2006) and Pirates of the Caribbean: At World’s End (2007). He is an Actor, Producer, three times World Martial Art Champion and CEO of Rayzor Edge Films.

We are looking for one minute movies made by yourself. Whether it be fiction, factual, thriller or a cartoon. With real people, animals or puppets whatever you choose. It is your movie.

Winners will have movies played and put on our website with a £50 Amazon Voucher.

Categories:
•15 and under
•16 and above

Closing date 14th April 2021

Please send entries to lucy.frost@treatsma.uk and marni.smyth@treatsma.uk

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more